Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.

Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Hsiao CC, Huang CC, Shih LH, Chen SW, Li SH.

BMC Cancer. 2018 Aug 20;18(1):837. doi: 10.1186/s12885-018-4731-9.

2.
3.

High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.

Cheng JC, Graber MS, Hsu FM, Tsai CL, Castaneda L, Lee JM, Chang DT, Koong AC.

Ann Surg Oncol. 2014 Jul;21(7):2361-8. doi: 10.1245/s10434-014-3611-z. Epub 2014 Mar 13.

PMID:
24623035
4.

Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.

Valencia Julve J, Alonso Orduña V, Escó Barón R, López-Mata M, Méndez Villamón A.

Clin Transl Oncol. 2006 Jan;8(1):22-30.

PMID:
16632436
5.

VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Tamura T, Kuwahara A, Yamamori M, Nishiguchi K, Nakamura T, Okuno T, Miki I, Manabe Y, Sakaeda T.

Int J Med Sci. 2012;9(10):833-7. doi: 10.7150/ijms.4914. Epub 2012 Nov 1.

6.

A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.

Zhao C, Lin L, Liu J, Liu R, Chen Y, Ge F, Jia R, Jin Y, Wang Y, Xu J.

Oncotarget. 2016 Aug 30;7(35):57310-57316. doi: 10.18632/oncotarget.9809.

7.

Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy.

Chen YH, Lu HI, Chien CY, Lo CM, Wang YM, Chou SY, Su YY, Shih LH, Li SH.

Sci Rep. 2017 Jan 30;7:41785. doi: 10.1038/srep41785.

8.

Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.

Hu G, Wang Z, Wang Y, Zhang Q, Tang N, Guo J, Liu L, Han X.

Drug Des Devel Ther. 2016 Jul 1;10:2129-36. doi: 10.2147/DDDT.S105441. eCollection 2016.

9.

Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.

Li J, Gong Y, Diao P, Huang Q, Wen Y, Lin B, Cai H, Tian H, He B, Ji L, Guo P, Miao J, Du X.

Radiat Oncol. 2018 Jan 22;13(1):12. doi: 10.1186/s13014-018-0958-5.

11.

The clinical impact of supraclavicular lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.

Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Huang CH, Shih LH, Chen SW, Li SH.

PLoS One. 2018 Jun 11;13(6):e0198800. doi: 10.1371/journal.pone.0198800. eCollection 2018.

12.

The clinical efficacy of consolidation chemotherapy for resectable esophageal squamous cell cancer after trimodality therapy.

Sun Y, Cheng S, Lu Y, Zheng X, Ye K, Ge H.

J Cancer Res Ther. 2016 Jan-Mar;12(1):90-5. doi: 10.4103/0973-1482.148687.

13.

Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer.

Xing L, Liang Y, Zhang J, Wu P, Xu D, Liu F, Yu X, Jiang Z, Song X, Zang Q, Wang W.

J Cancer Res Clin Oncol. 2014 May;140(5):867-72. doi: 10.1007/s00432-014-1615-5. Epub 2014 Mar 1.

PMID:
24578238
14.

Phase II study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed and cisplatin for locally advanced oesophageal squamous cell carcinoma.

Fu C, Li B, Guo L, Li H, Huang W, Gong H, Sun M, Wang Z, Zhou T, Liu C.

Br J Radiol. 2014 May;87(1037):20130656. doi: 10.1259/bjr.20130656. Epub 2014 Mar 26.

15.

Osteopontin Expression Is Associated with the Poor Prognosis in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy.

Chiu TJ, Lu HI, Chen CH, Huang WT, Wang YM, Lin WC, Li SH.

Biomed Res Int. 2018 Apr 30;2018:9098215. doi: 10.1155/2018/9098215. eCollection 2018.

16.

VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma.

Yoon MS, Nam TK, Lee JS, Cho SH, Song JY, Ahn SJ, Chung IJ, Jeong JU, Chung WK, Nah BS.

J Korean Med Sci. 2011 Apr;26(4):513-20. doi: 10.3346/jkms.2011.26.4.513. Epub 2011 Mar 28.

17.

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.

Zhou XL, Li YQ, Zhu WG, Yu CH, Song YQ, Wang WW, He DC, Tao GZ, Tong YS.

Sci Rep. 2017 Feb 14;7:42581. doi: 10.1038/srep42581.

18.

The status of perineural invasion predicts the outcomes of postoperative radiotherapy in locally advanced esophageal squamous cell carcinoma.

Ning ZH, Zhao W, Li XD, Chen LJ, Xu B, Gu WD, Shao YJ, Xu Y, Huang J, Pei HL, Jiang JT.

Int J Clin Exp Pathol. 2015 Jun 1;8(6):6881-90. eCollection 2015.

19.

The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.

Cox S, Hurt C, Grenader T, Mukherjee S, Bridgewater J, Crosby T.

Radiother Oncol. 2017 Oct;125(1):154-159. doi: 10.1016/j.radonc.2017.08.023. Epub 2017 Sep 8.

20.

Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.

Guo JC, Huang TC, Lin CC, Hsieh MS, Chang CH, Huang PM, Lee JM, Hsu FM, Chia-Hsien Cheng J, Wang HP, Yeh KH, Cheng AL, Hsu CH.

J Thorac Oncol. 2015 Oct;10(10):1481-9. doi: 10.1097/JTO.0000000000000651.

Supplemental Content

Support Center